Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

Neurology

Volumn 52, Issue 7, 1999, Pages 1397-1403

  Jack Jr , Clifford R ^a   Petersen, R C ^a   Xu, Y C ^a   O'Brien, P C ^a   Smith, G E ^a   Ivnik, R J ^a   Boeve, B F ^a   Waring, S C ^a   Tangalos, E G ^a   Kokmen, E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ESTROGEN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; COGNITIVE DEFECT; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL;

EID: 0344889207     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.7.1397     Document Type: Article

References (44)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
2. Petersen RC, smith GE, Ivnik RJ, Tangalos EG, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory impaired individuals. JAMA 1995; 273:1274-1278.
3. Smith GE, Petersen RC, Parisi JE, et al. Definition, course, and outcome of mild cognitive impairment. Aging Neuropsychol Cogn 1996;3:141-147.
4. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 1991;41: 1006-1009.
5. Masur D, Sliwinski M, Lipton R, et al. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994;44:1427-1432.
6. Linn R, Wolf P, Bachman D, et al. The 'preclinical phase' of probable Alzheimer's disease. Arch Neurol 1995;52:485-490.
7. Jacobs D, Sano M, Dooneief G, et al. Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology 1995;45:956-962.
8. Bowen J, Teri L, Kukull W, et al. Progression to dementia in patients with isolated memory loss. Lancet 1997;349:763-765.
9. DeCarli C, Kaye JA, Horwitz B, Rapoport SI. Critical analysis of the use of computer-assisted transverse axial tomography to study human brain in aging and dementia of the Alzheimer type. Neurology 1990;40:872-883.
10. Fox MC, Warrington EK, Freeborough PA. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996;119:2001-2007.
11. Kaye JA, Swihart T, Howieson D, Dame A. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997;48:1297-1304.
12. de Leon MJ, Golomb J, George AE, et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol 1993;14:897-906.
13. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
14. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but no senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639.
15. Welsh KA, Buters N, Hughes J, et al. Detection of abnormal memory decline in cases of alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 1991;38:278-281.
16. Jack CR Jr., Petersen RC, O'Brien PC, et al. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992;42:183-188.
17. Convit A, de Leon MH, Tarshis C, De Santi S, et al. Hippocampal volume losses in minimally impaired elderly. Lancet 1995;345:266.
18. Laakso MP, Soininen H, Partanen K, et al. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: correlation with memory functions. J Neural Transm 1995;9:73-86.
19. de Leon MJ, George AE, Golomb J, et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging 1997;18:1-11.
20. Petersen RC, Kokmen E, Tangalos EG, et al. Mayo Clinic Alzheimer's Disease Patient Registry. Aging 1990;2:408-415.
21. Weintraub S, Baratz R, Mesulam MM. Daily living activities in the assessment of dementia. In: Corkin S, Growdon JH, Usdin E, Wurtman RJ, eds. Alzheimer's disease: a report of progress in research. New York: Raven Press, 1982:189-192.
22. American Psychological Association. Diagnostic and statistical manual of mental disorders, revised. 3rd ed. Washington, DC: American Psychological Association, 1987.
23. Ivnik RJ, Malec JF, Smith GE, et al. Mayo's older Americans normative studies: WAIS-R, WMS-R, and AVLT norms for ages 56 through 97. Clin Neuropsychol 1992;6:1-103.
24. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
25. Jack CR Jr., Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997;49:786-794.
26. Jack CR Jr., Bentley M, Twomey CK, Zinsmeister AR. MR-based volume measurements of the hippocampal formation and anterior temporal lobe: validation studies. Radiology 1990;176:205-209.
27. Tsai MS, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer's disease. Am J Hum Genet 1994;54: 643-649.
28. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State.' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
29. Mattis S. Mental status examination for organic mental syndromes in the elderly patient. In: Bellak KT, ed. Geriatric psychiatry. New York: Grune & Stratton, 1976.
30. Wechsler D. Wechsler Memory Scale-revised. New York: Psychological Corporation, 1987.
31. Rey A. L'examen clinique en psychologie. Paris: Presse Universitaires de France, 1964.
32. Grober E, Buschke H, Crystal H. Screening for dementia by memory testing. Neurology 1988;38:900-903.
33. DeCarli C, Murphy DGM, Tranh M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995;45:2077-2084.
34. Corder EH, Saunders AM, Strittmatter WJ. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
35. O'Brien PC. A non-parametric test for association with censored data. Biometrics 1978;34:243-250.
36. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995;273:1354-1359.
37. Jacobs D, Sano M, Marder KEA. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994;44:1215-1220.
38. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996;46:661-665.
39. Benton AL, Hamsher K, Varney NR, et al. Contributions to neuropsychological assessment. New York: Oxford University Press, 1983.
40. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140: 256-261.
41. Tang M-X, Jacobs D, Stern Y, et al. Effect of estrogen during menopause on risk and age of onset of Alzheimer's disease. Lancet 1996;348:429-432.
42. Growdon J, Locasio J, Corkin S, et al. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996;47:444-448.
43. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942-947.
44. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.